A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients With Spasticity Due to Multiple Sclerosis
Latest Information Update: 13 May 2024
Price :
$35 *
At a glance
- Drugs Nabiximols (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Acronyms RELEASE MSS3
- Sponsors GW Pharmaceuticals; Jazz Pharmaceuticals Inc
- 14 Apr 2023 This trial has been completed in Czechia (End Date: 27 Feb 2023, according to European Clinical Trials Database record.
- 02 Apr 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 09 Mar 2023 Status changed to discontinued.